Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
CURRENT ASSETS:
Cash and cash equivalents	$ 15,146	$ 11,092
Accounts receivable, net of allowance for credit losses of $3,103 and $2,730 at 2020 and 2019, respectively	85,366	131,579
Inventories	42,908	50,163
Prepaid expenses	12,318	15,951
Income taxes receivable	8,091	6,527
Other current assets	6,060	5,925
TOTAL CURRENT ASSETS	169,889	221,237
PROPERTY, PLANT AND EQUIPMENT, net	117,123	123,506
RIGHT OF USE ASSETS	69,228	75,697
INTANGIBLES, net	8,651	17,450
GOODWILL	99,445	213,425
DEFERRED TAX ASSETS, net	74,939	67,312
OTHER ASSETS	51,539	56,046
TOTAL ASSETS	590,814	774,673
CURRENT LIABILITIES:
Current maturities of long-term debt	75,000
Accounts payable	22,806	35,611
Accrued payroll and related costs	33,473	26,689
Taxes other than payroll and income	5,646	8,366
Unearned revenues	8,021	13,381
Operating lease liabilities	11,807	11,841
Income taxes payable	7,234	6,324
Other current liabilities	8,149	9,382
TOTAL CURRENT LIABILITIES	172,136	111,594
LONG-TERM DEBT, net	189,566	305,283
LONG-TERM OPERATING LEASE LIABILITIES	56,649	64,660
DEFERRED COMPENSATION	49,316	50,485
DEFERRED TAX LIABILITIES, net	21,952	27,338
OTHER LONG-TERM LIABILITIES	29,486	33,173
COMMITMENTS AND CONTINGENCIES
EQUITY:
Preference shares, EUR 0.02 par value; 6,000,000 shares authorized, none issued or outstanding	0	0
Common shares, EUR 0.02 par value; 200,000,000 shares authorized, 44,796,252 issued and 44,494,696 outstanding at 2020 and 44,796,252 issued and 44,465,562 outstanding at 2019	1,148	1,148
Additional paid-in capital	61,465	51,872
Retained earnings	37,364	160,539
Accumulated other comprehensive income (loss)	(8,049)	(6,330)
Treasury shares, at cost, 301,556 at 2020 and 330,690 at 2019	(24,296)	(29,364)
Total Core Laboratories N.V. shareholders' equity	67,632	177,865
Non-controlling interest	4,077	4,275
TOTAL EQUITY	71,709	182,140
TOTAL LIABILITIES AND EQUITY	$ 590,814	$ 774,673